Vitadio
- Company typePrivate
- Founded2019
- HeadquartersPrague, Czechia
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Vitadio firmographics
Firmographics- Name
- Vitadio
- Legal name
- Vitadio s.r.o.
- Website
- https://vitad.io
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Vitadio industry classification
Industry- Product category
- Digital Therapeutics
- NAICS
- Software Publishers (513210)
- SIC
- Services-Health Services (8000), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)
- akta.pro secondary industries
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
Keywords
Where Vitadio is headquartered
LocationHeadquarters
- HQ city
- Prague
- HQ country
- Czechia
- HQ region
- Europe
Offices3 records
Markets served
Vitadio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Health Insurance Reimbursement (Germany): Digital therapeutic for type 2 diabetes is reimbursed by all statutory health insurers in Germany. Patients receive prescription-based access covered by public health insurance.
- Pharmaceutical Partnership Programs: Partnerships with pharmaceutical companies like AstraZeneca and Novo Nordisk where digital therapeutics augment their pharmacotherapy, creating differentiated treatment programs.
- International Expansion Revenue: Revenue from expanding into additional European markets including Czech Republic and Italy with prescription digital therapeutics.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
Vitadio product offering
Product offeringCore offering
Vitadio develops a prescription digital therapeutic for type 2 diabetes that combines AI-driven lifestyle modification with human dietitian support. The mobile application delivers personalized therapy through smart nudges, real-time diet feedback, and in-app social networking to help patients reverse insulin resistance and build healthy habits. The product is certified as a Class I medical device under MDR and is reimbursed by statutory health insurers in Germany.
Product overview
Vitadio offers a prescription digital therapeutic platform for type 2 diabetes, combining a proprietary AI model with proactive human support. The single main product is a digital therapy app that delivers personalized lifestyle modification through daily guidance, real-time diet feedback, and human dietitian support. The therapy is Class I medical device certified under MDR and covered by statutory health insurers in Germany. Vitadio also developed therapies for prediabetes and is expanding into additional lifestyle-related conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- Vitadio Digital Therapeutic A prescription digital therapeutic for type 2 diabetes that combines AI-driven lifestyle modification with human dietitian support, providing personalized therapy through smart nudges, real-time diet feedback, and in-app social networking.
Quantifiable outcome
- 0.8% HbA1c reduction in 6 months, comparable to modern antidiabetic medications
- +6 more outcomes
Companies that use Vitadio
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles4 records
Vitadio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Vitadio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- AstraZenecacorePharmaceutical partnership where AstraZeneca augments its pharmacotherapy with Vitadio digital therapeutics for achieving superior HbA1c and body weight reduction, improving quality of life, and driving better treatment adherence.
- Novo NordiskcorePartnership with Novo Nordisk combining their medications with Vitadio digital therapeutics to provide differentiation in the market and comprehensive treatment programs for type 2 diabetes patients.
- German Statutory Health InsurerscoreAll statutory health insurers in Germany provide reimbursement coverage for Vitadio digital therapeutic, including DAK, TK, AOK, Barmer, and 50+ other insurers. This enables prescription-based patient access at no direct cost.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Vitadio competitors and assessment
Company assessmentDirect peers
- HelloBetter: German digital therapeutics company offering prescription DTx reimbursed under the DiGA framework, with a primary focus on mental health but expanding into somatic conditions. Comparable on German DiGA reimbursement pathway, regulatory certification, and prescription-based B2B2C model.
- DarioHealth: Digital therapeutics platform combining AI, human coaching, and connected devices for diabetes, hypertension, and musculoskeletal conditions. Comparable on DTx category, B2B payer distribution, and chronic condition focus, though broader in indication scope.
- Omada Health: US-based digital therapeutics company specializing in diabetes prevention and chronic disease management through behavior change programs. Directly comparable on prescription DTx model, employer/payer reimbursement, and peer-reviewed clinical evidence approach for cardiometabolic conditions.
- mySugr (Roche): Acquired by Roche, mySugr is one of the most established diabetes management apps globally, serving millions of type 2 and type 1 diabetes patients with similar lifestyle, tracking, and coaching functionality. Directly comparable on therapeutic area, target patient population, and B2B2C payer-driven model.
- Sidekick Health: Nordic-origin digital therapeutics platform addressing type 2 diabetes, cardiovascular disease, and cancer through gamified behavior change with both AI and human coaching. Comparable on chronic condition DTx model, European payer reimbursement, and pharma partnership strategy.
- Oviva: European digital health company offering dietitian-led digital therapeutic programs for type 2 diabetes, obesity, and metabolic conditions across Switzerland, Germany, UK, and France. Closely comparable on clinical evidence generation, statutory health insurance reimbursement in Germany, and hybrid AI/human coaching model.
- Perfood: German digital therapeutic company developing prescription DTx for migraine, prediabetes, and other metabolic conditions with AI-driven personalization. Comparable on German DTx regulatory pathway, AI personalization approach, and cardiometabolic therapeutic focus.
Broad incumbents
- Roche Diabetes Care: Global diabetes device and digital health division of Roche, owning mySugr and Accu-Chek, operating at vastly larger scale in the same therapeutic area. Comparable as a broad incumbent with overlapping digital health ambitions for type 2 diabetes patients, but with a device-and-pharma portfolio rather than a pure DTx focus.
- Novo Nordisk (Digital Health initiatives): Global pharmaceutical leader in diabetes and obesity (Ozempic, Wegovy) actively building digital companion products and partnerships. Currently a partner of Vitadio, but also a potential competitor or acquirer given its strategic push into digital health for chronic disease management.
Emerging players
- Kaia Health: Digital therapeutics company offering AI-driven musculoskeletal pain management and COPD programs, with expanding focus into chronic conditions. Adjacent peer via shared DTx regulatory model, AI personalization, and B2B payer distribution, though focused on different primary indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Vitadio social profiles
Digital presenceVitadio compliance and trust
Trust signalCompliance4 records
Vitadio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vitadio leadership team
Management profileNumber of profiles
Profiles6 records
Vitadio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vitadio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vitadio
What does Vitadio do?
Vitadio develops a prescription digital therapeutic for type 2 diabetes that combines AI-driven lifestyle modification with human dietitian support. The mobile application delivers personalized therapy through smart nudges, real-time diet feedback, and in-app social networking to help patients reverse insulin resistance and build healthy habits. The product is certified as a Class I medical device under MDR and is reimbursed by statutory health insurers in Germany.
Is Vitadio a public or private company?
Vitadio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vitadio founded?
Vitadio was founded in 2019. It employs 11 to 50 people.
Where is Vitadio based?
Vitadio is headquartered in Prague, Czechia, in the Europe region.
How does Vitadio make money?
Three revenue lines are on record. Health Insurance Reimbursement (Germany) is the primary driver. The others are pharmaceutical Partnership Programs and international Expansion Revenue.
Who are Vitadio's main competitors?
Direct peers on record are HelloBetter, DarioHealth, Omada Health, mySugr (Roche), Sidekick Health, Oviva and Perfood. Broad incumbents are Roche Diabetes Care and Novo Nordisk (Digital Health initiatives). Kaia Health is listed as an emerging player.
Does Vitadio have an API?
No public API is recorded for Vitadio.
What industry is Vitadio in?
Vitadio's product category is Digital Therapeutics. Its primary akta.pro industry code is HLALAFAF, Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 513210 and its SIC code is 8000.